Find policies, billing codes, payers, states, and providers
CPT 0445U: Elecsys pTau181/Abeta42 CSF Ratio Assay
CPT code 0445U is a Proprietary Laboratory Analyses (PLA) code for the Elecsys® Phospho–Tau (181P) CSF and β–Amyloid (1–42) CSF II Ratio test from Roche Diagnostics. The assay produces a pTau181/Abeta42 ratio from cerebrospinal fluid using an electrochemiluminescent immunoassay (ECLIA). This biomarker ratio is used in the clinical evaluation of patients with cognitive impairment and may inform diagnostic discussions about Alzheimer disease pathology.
Key national payers examined include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise briefing on the clinical context for CSF biomarker testing, the specific scope and exclusivity implied by the PLA code, and what the code represents for laboratory services and sites of care. The publication summarizes payer coverage considerations, coding and billing practice implications, and the typical service settings where the test is performed. Policy updates and benchmark comparisons relevant to PLA-coded, manufacturer-specific laboratory tests are outlined to help clinical administrators and billing professionals understand how this code fits into broader laboratory and cognitive neurology workflows.
Data not available in the input for associated taxonomies, ICD-10 diagnoses, related codes, and service line specifics.
Customize your policy alerts
Sign up for cpt 0445U policy alerts
Get alerted when payer policies referencing 0445U are released or updated.
Monitor payer policy activity
Billing Code Overview
CPT code 0445U is a Proprietary Laboratory Analyses (PLA) code that applies exclusively to the Elecsys® Phospho–Tau (181P) CSF (pTau181) and β–Amyloid (1–42) CSF II (Abeta 42) Ratio test produced by Roche Diagnostics Operations Inc. The assay uses cerebrospinal fluid and an electrochemiluminescent immunoassay (ECLIA) method to generate a pTau181/Abeta42 ratio value that may assist clinicians evaluating patients with signs of cognitive impairment.
-
Service type: Clinical laboratory test — cerebrospinal fluid biomarker assay
-
Typical site of service: Inpatient or outpatient clinical laboratory settings where cerebrospinal fluid specimens are collected and analyzed